Reuters: Regulatory News: Bayer says FDA requests more data on Xarelto for stent patients

Changes are afoot at Blogtrottr! By popular request, we're bringing in paid plans with some cool new features (and more on the way). You can read all about it in our blog post.

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Bayer says FDA requests more data on Xarelto for stent patients Jun 28th 2013, 12:49 FRANKFURT, June 28 | Fri Jun 28, 2013 8:49am EDT FRANKFURT, June 28 (Reuters) - Bayer said the U.S. Food and Drug Administration has put on hold a decision over the use of anti-clotting pill Xarelto to prevent stent thrombosis in patients suffering from acute coronary syndrome, requesting more information. Bayer said on Friday it was confident that together with development partner Johnson & Johnson it can address the questions in the FDA's so-called "complete response letter".

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions